JGC
TNGX icon

J. Goldman & Co’s Tango Therapeutics TNGX Stock Holding History

J. Goldman & Co’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-108,000
Closed -$907K – 742
2025
Q3 		$907K Buy
+108,000
New +$731K 0.02% 343

Other funds holding TNGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

J. Goldman & Co's TNGX Position: Q4 2025 in Review

J. Goldman & Co sold out of Tango Therapeutics (TNGX) in Q4 2025, closing a stake of 29,036 shares — an estimated $244K sold.

J. Goldman & Co first reported a position in TNGX in Q3 2025 and held it in 1 quarter. The position peaked at $244K in Q3 2025. 170 funds tracked by Wall St. Rank hold TNGX as of Q4 2025.

  • J. Goldman & Co reported no remaining Tango Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 29,036 Tango Therapeutics shares in Q4 2025, an estimated $244K.
  • J. Goldman & Co first reported a position in Tango Therapeutics in Q3 2025 and held it in 1 quarter.
  • J. Goldman & Co's Tango Therapeutics position peaked at $244K in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.